Instructions and schemes for the use of Kagocel for children and adults with influenza and ARVI

INSTRUCTIONS

Kagocel - instruction

Kagocel

REGISTRATION NUMBER: TRADING NAME OF THE FACILITY: Kagocel® (Kagocel® ) INTERNATIONAL NON-PROPERTY NAME: no. CHEMICAL NAME: Sodium salt of copolymer (1 → 4) - 6- 0-carboxymethyl-β-D-glucose, (1 → 4) - β-D-glucose and (21 → 24) -2,3,14,15, 21,24,29,32-octahydroxy-23- (carboxymethoxymethyl) -7, 10-dimethyl-4, 13-di (2-propyl) - 19,22,26,30,31 - pentaoxaheptacyclo [23.3.2.2 16.20 .0 5.28 .0 8.27 .0 9.18 .0 12.17 ] dotriaconta-1,3,5 (28), 6,8 (27), 9 (18), 10, 12 (17), 13,15-decaene. DOSAGE FORM: Tablets. COMPOSITION: Active substance: Kagocel® 12 mg. Excipients: potato starch - 10 mg, calcium stearate - 0.65 mg, Ludipress (composition: lactose monohydrate, povidone (Kollidon 30), crospovidone (Kollidon CL)) - until a tablet weighing 100 mg is obtained. DESCRIPTION: Tablets from white with a brownish tinge to light brown, round, biconvex, interspersed with brown. PHARMACOTHERAPEUTIC GROUP: Antiviral agent. ATX CODE: [J05AX]

PHARMACOLOGICAL PROPERTIES

PHARMACODYNAMICS The main mechanism of action Kagocela® is the ability to induce the production of interferons. Kagocel® causes the formation in the human body of the so-called late interferons, which are a mixture of α- and β-interferons with high antiviral activity. Kagocel® causes the production of interferons in almost all populations of cells involved in the antiviral response of the body: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When taken orally in one dose Kagocela® the titer of interferons in the blood serum reaches its maximum values ​​after 48 hours. Interferon response of the body to administration Kagocela® characterized by prolonged (up to 4-5 days) circulation of interferons in the bloodstream. The dynamics of the accumulation of interferons in the intestine when taken orally Kagocela® does not coincide with the dynamics of circulating interferon titers. In the blood serum, the production of interferons reaches high values ​​only 48 hours after ingestion. Kagocela® , while in the intestine, the maximum production of interferons is noted after 4 hours. Kagocel® , when administered in therapeutic doses, is non-toxic, does not accumulate in the body. The drug does not possess mutagenic and teratogenic properties, is not carcinogenic and does not have an embryotoxic effect. Most effective in treatment Kagocel® is achieved when it is prescribed no later than the 4th day from the onset of an acute infection. For prophylactic purposes, the drug can be used at any time, including immediately after contact with the infectious agent.

PHARMACOKINETICS 24 hours after administration into the body Kagocel® accumulates mainly in the liver, to a lesser extent in the lungs, thymus, spleen, kidneys, lymph nodes. Low concentration is observed in adipose tissue, heart, muscles, testes, brain, blood plasma. Low content Kagocela® in the brain is explained by the high molecular weight of the drug, which makes it difficult for its penetration through the blood-brain barrier. In blood plasma, the drug is mainly in a bound form. With daily repeated administration Kagocela® the volume of distribution varies widely in all investigated organs. The accumulation of the drug in the spleen and lymph nodes is especially pronounced. When taken orally, about 20% of the administered dose of the drug enters the general bloodstream. The absorbed drug circulates in the blood, mainly in the form associated with macromolecules: with lipids - 47%, with proteins - 37%. The unbound part of the drug is about 16%. Excretion: the drug is excreted from the body mainly through the intestines: after 7 days after administration, 88% of the administered dose is excreted from the body, including 90% through the intestines and 10% - by the kidneys. The drug was not found in the exhaled air.

INDICATIONS FOR USE Kagocel® used in adults and children aged 3 years and older as a preventive and therapeutic agent for influenza and other acute respiratory viral infections (ARVI), as well as a therapeutic agent for herpes in adults.

CONTRAINDICATIONS - Pregnancy and lactation period; - Age up to 3 years; - Hypersensitivity to the components of the drug; - Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

DOSAGE AND APPLICATION

Flu and ARVI treatment

Prevention of influenza and ARVI

For adults

  • x 6
  • x 6
  • x 6
  • x 6
  • x 6
  • -
  • -

Inside, regardless of food intake. For the treatment of influenza and acute respiratory viral infections, adults are prescribed in the first two days - 2 tablets 3 times a day, in the next two days - one tablet 3 times a day. In total, the course - 18 tablets, the duration of the course - 4 days. Prevention of influenza and acute respiratory viral infections in adults is carried out in 7-day cycles: two days - 2 tablets once a day, a break for 5 days, then repeat the cycle. The duration of the preventive course is from one week to several months. For the treatment of herpes in adults, 2 tablets are prescribed 3 times a day for 5 days. In total, the course - 30 tablets, the duration of the course - 5 days. For the treatment of influenza and acute respiratory viral infections, children aged 3 to 6 years are prescribed in the first two days - 1 tablet 2 times a day, in the next two days - one tablet once a day. In total, the course - 6 tablets, course duration - 4 days. For the treatment of influenza and acute respiratory viral infections, children aged 6 years and older are prescribed in the first two days - 1 tablet 3 times a day, in the next two days - one tablet 2 times a day. In total for the course - 10 tablets, the duration of the course - 4 days. Prevention of influenza and ARVI in children aged 3 years and older is carried out in 7-day cycles: two days - 1 tablet once a day, 5 days off, then repeat the cycle. The duration of the preventive course is from one week to several months.

SIDE EFFECT Development of allergic reactions is possible. If any of the side effects indicated in the instructions are aggravated, or you notice any other side effects not listed in the instructions, tell your doctor about it.

POSSIBILITY AND FEATURES OF USE BY PREGNANT WOMEN, WOMEN DURING BREASTFEEDING Due to the lack of necessary clinical data Kagocel® not recommended for use during pregnancy and lactation.

INFLUENCE ON ABILITY TO DRIVE VEHICLES, MECHANISMS The effect of the drug on the ability to drive vehicles, mechanisms has not been studied.

OVERDOSE In case of accidental overdose, it is recommended to prescribe an abundant drink, induce vomiting.

INTERACTION WITH OTHER DRUGS Kagocel® goes well with other antiviral drugs, immunomodulators and antibiotics (additive effect).

SPECIAL INSTRUCTIONS To achieve a therapeutic effect, taking Kagocela® should start no later than the fourth day from the onset of the disease.

RELEASE FORM Tablets, 12 mg. On 10 tablets in a blister strip of a film of polyvinyl chloride / polyvinylidene chloride and aluminum foil with a heat-sealable coating. 1, 2 or 3 blister packs together with instructions for use are placed in a pack.

SHELF LIFE 4 years. After the expiry date indicated on the package, the drug should not be used.

STORAGE CONDITIONS In a dark place at a temperature not exceeding 25 C. Keep out of the reach of children.

TERMS OF RELEASE FROM PHARMACIES Without a doctor's prescription.

LEGAL ENTITY IN WHICH THE REGISTRATION CERTIFICATE IS ISSUED NEARMEDIC PLUS LLC, Russia, 125252, Moscow, st. Aircraft Mikoyan, 12.

MANUFACTURING COMPANY Manufacturer 1: NEARMEDIC PLUS LLC, Russia, 125252, Moscow, st. Aviakonstruktora Mikoyan, 12 Address of the place of production: Russia, 123098, Moscow, st. Gamalei, 18, p. 4, 10, 11, 18, 33. Manufacturer 2: Hemofarm LLC, Russia, 249030, Kaluga region, Obninsk, Kiev highway, 62. Manufacturer 3: NEARMEDIC LLC PHARMA ”, Russia, 249030, Kaluga region, Obninsk, st. Koroleva, 4, office 402. The address of the place of production: Russia, 249008, Kaluga region, Borovsky district, near the village. Malanino, Kievskoe highway, bldg. 6.

CUSTOMER CLAIMS SEND TO ADDRESS NEARMEDIC PLUS LLC, Russia, 125252, Moscow, st. Aviakonstruktora Mikoyan, 12, phone / fax: +7 (495) 385-80-08, e-mail: [email protected]

Kagocel is a drug belonging to the group of antiviral drugs. Promotes the production of alpha and beta interferons. Thanks to this, the work of the immune system is activated and the synthesis of viral microorganisms is inhibited.

kagocel_new.jpg

Release form and composition

Kagocel is available in tablet form. Shape: biconvex, round. Color: cream or brown, small splashes are allowed. The blister contains 10 tablets. The package contains 1 or 2 plates.

Active ingredient: kagocel. Excipients: potato starch, calcium stearate, lactose monohydrate, povidone, crospovidone.

pharmachologic effect

Kagocel belongs to the group of antiviral drugs. The basis of the active substance of the drug is plant compounds. Kagocel has the following therapeutic effects:

  • immunomodulatory;
  • antiviral;
  • antimicrobial;
  • radioprotective.

Pharmacodynamics

The action of Kagocel is based on the stimulation of the production of alpha and beta interferons. They provide the antiviral activity of the drug. After the drug is ingested, a long-term interferon response is formed. This means that interferons circulate in the body for a long time. The maximum concentration of Kagocel in blood plasma is detected 2 days after its administration.

Kagocel is non-toxic and does not accumulate in the body, provided that it is taken in therapeutic doses. In order to achieve the maximum effect of the drug, it must be taken at the first signs of the disease.

Pharmacokinetics

1 day after taking Kagocel, it is found in organs that stimulate the body's immune response. These include the spleen, kidneys, lymph nodes, liver, lungs, and thymus. In small concentrations, the drug is found in the heart, brain and testes.

The maximum amount of interferons in the blood plasma is recorded 2 days after taking Kagocel. They can be found in the intestines after 4 hours. The interferon response lasts for 5 days. All this time, interferons circulate in the body. Excretion of the drug occurs through the intestines. Most of the drug is excreted in the feces, the rest in the urine.

Indications for use of Kagocel

Kagocel is used for both treatment and prevention of various viral diseases. The indications for its appointment include:

  • flu;
  • cold symptoms;
  • adenovirus;
  • rotavirus;
  • herpes simplex.

Dosage, frequency of administration and duration of the course depend on various factors. These include the type of disease and its severity. It is recommended that you consult your doctor before taking this medicine.

Kagocel is administered orally. The tablets are taken with a sufficient amount of water. General therapeutic regimens for taking the drug include the following recommendations:

  1. For the treatment of influenza and SARS in the first 2 days, 2 tablets are prescribed 3 times a day. In the next 2 days, the intake is reduced to 1 tablet 3 times a day. The course of treatment is 4 days.
  2. For the treatment of influenza and acute respiratory viral infections, children aged 3-6 years in the first 2 days are prescribed 1 tablet 2 times a day, followed by a decrease in the dosage to 1 tablet 1 time a day. The course of treatment is 4 days. Children over 6 years old in the first 2 days of treatment are prescribed 1 tablet 3 times a day. In the remaining 2 days, take 1 tablet 2 times a day.
  3. In order to prevent acute respiratory viral diseases, 2 tablets are prescribed 1 time per day for 2 days. For children, the prophylactic dosage of Kagocel is 1 tablet 1 time per day for 2 days.

Contraindications

The main restrictions for the appointment of Kagocel are:

  • individual intolerance to the components of the drug;
  • pregnancy and lactation;
  • children less than 3 years old;
  • lactose intolerance;
  • lactase deficiency;
  • glucose-galactose malabsorption.

Side effects

Kagocel is well tolerated. Side effects are extremely rare. Among them are noted:

  • hives;
  • itchy skin;
  • Quincke's edema.

If any of the above symptoms appear, it is recommended to stop taking the drug and consult a doctor. Severe allergic reactions require hospitalization and symptomatic treatment.

Overdose

If the therapeutic dosage of Kagocel is exceeded, symptoms of an overdose may occur. These include:

  • nausea;
  • vomiting is possible;
  • pain in the abdomen;
  • dizziness;
  • pallor of the skin.

If the drug has been recently taken, you must drink enough water and induce vomiting. Symptomatic therapy of an overdose is to take absorbent drugs.

Interaction

Kagocel, when interacting with other drugs, enhances their effect. For example, the joint appointment of Kagocel with antibacterial drugs (Amoxiclav, Azithromycin, Amoxicillin) leads to an increase in their effectiveness.

Kagocel interacts well with antipyretic drugs (Teraflu, Aspirin, Paracetamol, Ibuprofen, Ibuklin, Anvimax). This combination is often used to relieve flu and SARS symptoms.

Kagocel's analogs

In case of individual intolerance or the presence of contraindications to the use of Kagocel, the drug can be replaced with drugs similar in effect. These include:

  • Ingavirin;
  • Arbidol;
  • Ergoferon;
  • Cycloferon;
  • Remantadine;
  • Amiksin;
  • Tsitovir;
  • Trekrezan;
  • Tamiflu;
  • Arpeflu;
  • Polyoxidonium;
  • Rinza;
  • Lavomax;
  • Bronchomunal;
  • Oscillococcinum;
  • Antigrippin;
  • Anvimax.

Which is better: Kagocel or Ingavirin?

Ingavirin is an antiviral drug. The active ingredient of the drug is pentanedioic acid imidazolylethanamide. Ingavirin has an immunomodulatory, antiviral and anti-inflammatory effect. It is produced in the form of capsules with different dosages of the active substance. The drug helps to accelerate the elimination of viruses from the body, shortens the duration of the infection and reduces the risk of complications. Ingavirin enhances the effect of antibacterial drugs. The main indications for prescribing a medicinal product include:

  • influenza A and B;
  • adenovirus;
  • parainfluenza;
  • respiratory syncytial infection;
  • prevention of acute respiratory viral diseases.

Kagocel and Ingavirin belong to the group of antiviral drugs. The drugs are approved for use during pregnancy and lactation. Medicines are well tolerated, in rare cases they cause signs of an allergic reaction.

Ingavirin is available in capsule form. Kagocel is produced in tablet form. Ingavirin's shelf life is 2-3 years, depending on the dosage. Kagocel can be stored for 4 years from the date of production. It is recommended to consult a doctor before purchasing drugs in pharmacies. The specialist will be able to assess the severity of the condition, prescribe the correct dosage of the medication and determine the duration of the course of treatment.

Which is better: Kagocel or Arbidol?

Arbidol is an antiviral agent with an immunostimulating effect. The active substance of the drug is umifenovir hydrochloride. It belongs to the synthetic analogs of interferon. Arbidol blocks the multiplication of viral cells, helps to reduce the severity of symptoms of the disease and makes up for the lack of natural interferons. The main indications for prescribing the drug include the treatment and prevention of acute respiratory viral diseases. Arbidol is available in the form of capsules, tablets and powder for the preparation of a suspension for oral administration.

Kagocel and Arbidol are representatives of the group of antiviral drugs. Both drugs are used for the treatment and prevention of acute infectious and viral diseases. The action of drugs is based on the activation of the immune system.

Arbidol blocks infection, and also helps to eliminate the main causes of the disease. The mechanism of action of Kagocel is based on the activation of the immune system to fight against viral microorganisms. Arbidol is available in the form of capsules, tablets and powder for suspension preparation. Kagocel is produced in tablet form. The joint use of drugs is not recommended due to the increased risk of overdose.

Which is better: Kagocel or Ergoferon?

Ergoferon is a combined drug used to treat viral diseases. It has immunomodulatory, antihistamine, anti-inflammatory and antiviral effects. Available in the form of lozenges. The main indications for the appointment of Ergoferon are the treatment and prevention of diseases caused by the following viruses:

  • influenza A and B;
  • adenovirus;
  • coronavirus;
  • respiratory syncytial virus;
  • herpes infection;
  • rotavirus;
  • enterovirus;
  • complex therapy of bacterial infections.

Kagocel and Ergoferon belong to the group of antiviral and immunomodulatory drugs. They are prescribed for the treatment and prevention of viral diseases of various etiologies. One of the differences between the drugs is in their form of release. Kagocel is produced in the form of tablets for oral administration. Ergoferon is available in the form of lozenges. Kagocel is approved for use in children from 3 years old, Ergoferon - from 6 months. Kagocel retains its effectiveness both in the initial stages of the disease and in the active phase. It is recommended to start using Ergoferon when the first signs of malaise appear.

Which is better: Kagocel or Cycloferon?

Cycloferon belongs to the group of immunostimulating drugs. The active ingredient of the drug is meglumine acridone acetate. Available in the form of tablets and solution for injection. Cycloferon has antiviral, immunomodulatory, antiproliferative and anti-inflammatory effects. The drug reduces the production of pathogenic microorganisms and increases the body's resistance to various bacterial infections. The indications for the appointment of Cycloferon are:

  • acute respiratory viral diseases;
  • flu;
  • herpes.

The drug is equally effective for both treatment and prevention of morbidity. In pediatric practice, Cycloferon is prescribed from 4 years old. Contraindications for the appointment of the drug are pregnancy, lactation, individual intolerance to the components of the drug, cirrhosis of the liver in the stage of decompensation and age under 4 years.

Kagocel and Cycloferon have antiviral and immunostimulating effects. Drugs are prescribed for the treatment and prevention of viral diseases. The differences between drugs are in the active substances, mechanisms of action and the form of release. The active ingredient of Cycloferon is meglumine acridone acetate. As part of Kagocel, the active substance is Kagocel. Cycloferon is produced in the form of tablets and solution for injection. Kagocel is available in tablet form.

Which is better: Kagocel or Remantadin?

Another representative of the group of antiviral drugs is Remantadine. The active substance of the drug is rimantadine hydrochloride. Available in the form of tablets and capsules. The action of the drug is based on the introduction of a viral cell into the DNA with the subsequent suppression of its activity. Remantadine is prescribed for the treatment and prevention of acute viral diseases and early stages of influenza. Restrictions for its use are nephritis, hepatitis, pregnancy and lactation.

Kagocel and Remantadin belong to the group of antiviral drugs. Both drugs are available in tablet form. The differences between them are as follows:

  1. The action of Remantadine is to suppress the multiplication of the viral cell. As a result of taking Kagocel, interferons are produced, which trigger the body's immune system. Due to this, the number of viral pathogens decreases and the severity of the clinical symptoms of the disease decreases.
  2. Kagocel is effective against various viral microorganisms. The action of Remantadine is directed only against the type A virus, which causes the symptoms of influenza and SARS.
  3. Remantadine has more contraindications than Kagocel.
  4. Kagocel is approved for use in children from 3 years of age, Remantadin - from 7 years.

Which is better: Kagocel or Amiksin?

Amiksin is an antiviral immunostimulating drug. As part of the drug, the active substance is tilorone. Amiksin has an immunomodulatory and antiviral effect. The drug stimulates the production of interferon, thereby blocking the multiplication of viral cells. Available in tablet form. The medicine is used to treat and prevent various diseases caused by viral infections. Amiksin is contraindicated for use during pregnancy and lactation, as well as under the age of 7 years.

Kagocel and Amiksin belong to the same pharmacological group. The action of the drugs is based on stimulating the production of interferons. Both drugs are available in tablet form. The differences between the drugs are in the active substances and the mechanism of action. Amiksin is able to inhibit the reproduction of viruses even before the production of interferon. The drug is included in the list of essential medicines of the Russian Federation. Kagocel was removed from the list after 2015. In pediatric practice, Amiksin is used from the age of 7, and Kagocel - from the age of 3.

Which is better: Kagocel or Tsitovir?

Citovir is an antiviral and immunomodulatory agent. The active substance of the drug is ascorbic acid. Suppression of inflammatory processes occurs due to the fact that Cytovir helps to stabilize capillary permeability. Excipients of the drug enhance its effect. As a result, the metabolism in the body is accelerated and the work of nonspecific immunity is normalized. The drug is prescribed for the treatment and prevention of acute respiratory viral diseases, as well as influenza A and B. Citovir is not recommended for use during pregnancy and lactation, as well as in the presence of vascular pathology, diabetes mellitus, gastric ulcer and an allergic reaction to vitamin C. In pediatric In practice, the drug has been used since 1 year. Citovir is produced in the form of capsules, powder and syrup for oral administration.

Kagocel and Tsitovir are prescribed for the production of interferons. Both drugs can help lower blood pressure. As a result, while taking medications, nausea, weakness, dizziness and a sharp decline in strength temporarily appear. The differences between the medicines are as follows:

  1. Kagocel is produced in tablet form. Citovir is available in the form of capsules, powder and syrup for oral administration.
  2. Citovir contains natural ingredients that allow you to use it for young children.
  3. Kagocel has an aggressive effect on the human body. The result is a rapid production of interferon. This effect makes it possible to alleviate the symptoms of the disease in the shortest possible time.

Before purchasing a medicine, it is recommended to consult a doctor. The specialist will be able to assess the severity of the condition and prescribe the correct treatment.

Which is better: Kagocel or Trekrezan?

Trekrezan belongs to the group of immunomodulatory drugs with adaptogenic properties. The active substance of the drug is oxyethylammonium methylphenoxyacetate. Trekrezan stimulates the production of interferons. As a result, immunity increases, general condition improves, appetite normalizes. The indications for prescribing a medicinal product are:

  • treatment and prevention of acute respiratory viral diseases;
  • stimulation of physical and mental performance;
  • reduction of symptoms of overwork;
  • increasing the body's resistance to various stressful situations;
  • immunodeficiency states;
  • complex therapy of poisoning with salts of heavy metals;
  • complex therapy of withdrawal symptoms.

Kagocel and Trekrezan promote the production of interferon. Thus, the drugs increase the protective functions of the body, activating it to fight viral microorganisms. Medicines are available in tablet form and are not addictive. Kagocel and Trekrezan are not recommended for use during pregnancy and lactation. The differences between the drugs are as follows:

  • Kagocel is approved for use in children from 3 years of age. Trekrezan has been used since the age of 12;
  • Trekrezan is a prescription drug. Kagocel is dispensed without a doctor's prescription;
  • Kagocel stimulates the production of alpha and beta interferons. Action Trekrezan is aimed at the production of alpha and gamma interferons;
  • if it is necessary to increase stress resistance, it is recommended to use Trekrezan. The drug has a greater number of additional actions in comparison with Kagocel.

Which is better: Kagocel or Tamiflu?

Tamiflu is an antiviral agent. The active substance of the drug is oseltamivir. Tamiflu is available in capsule and powder form for oral suspension. To achieve a greater effect, it is recommended to start taking the drug on the first day after the onset of signs of the disease. The indications for the appointment of Tamiflu are the treatment and prevention of influenza and ARVI. The drug is allowed for use during pregnancy and lactation, but under strict indications and under the supervision of a doctor.

Kagocel and Tamiflu are antiviral drugs. The drugs have different active substances and mechanisms of action. In the presence of strict indications, Tamiflu is allowed for administration during pregnancy and lactation. Kagocel is produced in tablet form. Tamiflu is available in capsule and powder form for suspension. The doctor decides which of the drugs will be more effective in a given situation. Self-medication can lead to serious complications.

Which is better: Kagocel or Arpeflu?

Arpeflu is an antiviral drug that has an immunomodulatory and anti-influenza effect. Thanks to the active components of the drug, immunity is stimulated, the body's resistance to various viral infections increases. Arpeflu has the ability to suppress influenza A and B viruses. As a result of taking the drug, the risk of developing post-influenza complications is reduced. Available in pill form. The main indications for the appointment of Arpeflu are:

  • symptoms of acute respiratory viral infection;
  • immunodeficiency states;
  • influenza A and B;
  • prevention of infectious complications in the postoperative period;
  • prevention of immunodeficiency;
  • complex therapy of herpes infection.

Kagocel and Arpeflu are used if there are signs of ARVI and influenza. The drugs have antiviral and immunomodulatory effects. Available in tablet form. The differences between them lie in the active substances and the mechanism of action.

Which is better: Kagocel or Polyoxidonium?

Polyoxidonium is an antiviral agent. The drug has an immunomodulatory, antioxidant and anti-inflammatory effect. The active ingredient of the drug is azoxymer bromide. Polyoxidonium is available in the form of tablets, lyophilisate for preparation of solution for injection, as well as vaginal and rectal suppositories. The drug increases the body's resistance to infectious agents. The indications for its appointment are:

  • prevention, treatment of ARVI and influenza;
  • endometritis;
  • cystitis;
  • pyelonephritis;
  • urethritis;
  • tuberculosis;
  • recovery period after chemotherapy;
  • complex therapy of burns, fractures and frostbite.

Kagocel and Polyoxidonium belong to the same pharmacological group. The drugs are well tolerated. Medicines are not recommended for use during pregnancy and lactation. The joint appointment of antiviral drugs with antibiotics or antifungal agents enhances the effect of the latter. The differences between the drugs are as follows:

  • Kagocel promotes the activation of alpha and beta interferons. Polyoxidonium launches all the links of the immune system;
  • Kagocel is allowed to be taken by patients from 3 years of age, Polyoxidonium - from 12 years.
  • Kagocel is available in tablet form. Polyoxidonium in the form of tablets, rectal and vaginal suppositories, as well as lyophilisate for injection.

Which is better: Kagocel or Rinza?

Rinza is a combined preparation. The active components of the drug are caffeine, paracetamol, phenylephrine and chlorphenamine. Thanks to its components, Rinza has the following actions:

  • antihistamine;
  • psychostimulating;
  • analgesic;
  • antipyretic;
  • anti-congestive.

The drug is available in the form of tablets and powder for solution preparation. The main indication for prescribing Rinza is the treatment and prevention of ARVI and influenza symptoms. The drug is not recommended for use during pregnancy and lactation, as well as under the age of 15 years.

Kagocel and Rinza are used for signs of colds and flu. The preparations contain various active substances. They differ in the mechanism of action and the form of release. Kagocel is used as etiotropic therapy, while Rinza is used for symptomatic therapy. Kagocel promotes the activation of interferons and increases the protective functions of the body. Rinza reduces pain and body temperature, has an analgesic effect, and relieves symptoms of intoxication. Complex therapy of acute viral diseases does not exclude the joint use of these drugs.

Which is better: Kagocel or Lavomax?

Lavomax belongs to the group of antiviral immunomodulatory drugs. The active ingredient of the drug is tilorone dihydrochloride. Lavomax activates the synthesis of interferon in the human body, as well as the protective functions of the body. The drug stimulates stem cells and enhances antibody production. The drug is effective against various viral infections. The indications for the appointment of Lavomax are:

  • herpes virus;
  • acute viral respiratory diseases;
  • influenza A and B.

The drug is used for both therapeutic and prophylactic purposes. Available in tablet form. Dosage, frequency of admission and duration of the course are determined individually.

Kagocel and Lavomax belong to the same pharmacological group. They have antiviral and immunostimulating effects. Medicines activate the production of interferon and increase the protective functions of the body. Kagocel and Lavomax are not recommended to be prescribed during pregnancy and lactation. The difference between them lies in the active substances.

Which is better: Kagocel or Bronchomunal?

Bronchomunal is a drug belonging to the group of immunostimulants. The composition of the drug contains bacterial lysates. Bronchomunal activates the immune system, increasing the body's resistance to infectious agents. Thanks to the drug, the duration of the disease is reduced, the risk of exacerbation of chronic pathology is reduced. The indications for prescribing a medicinal product are:

  • acute infectious diseases of the upper respiratory tract;
  • prevention of exacerbations of chronic bronchitis.

Bronchomunal is not recommended for use during pregnancy and lactation. The drug is available in capsules of various dosages.

Kagocel and Bronchomunal belong to the same pharmacological group of drugs. They stimulate the protective functions of the body, thereby increasing its resistance to various viral and bacterial cells. Medicines are prescribed when there are signs of acute respiratory viral diseases. Kagocel is available in tablet form. Bronchomunal is produced in capsule form. It is recommended that you consult your doctor before taking medications. The specialist will be able to choose the dosage and get ahead of the duration of the course of treatment.

Which is better: Kagocel or Oscillococcinum?

Oscillococcinum is a drug belonging to the group of homeopathic medicines. It is prescribed for the treatment of ARVI and influenza. The preparation contains duck liver and heart extract. Oscillococcinum has no restrictions for use during pregnancy and lactation. However, the drug should be taken strictly according to the indications.

Kagocel and Oscillococcinum belong to the group of antiviral drugs. Prescribed for the treatment of influenza and acute respiratory viral diseases. Both drugs have immunomodulatory effects. The differences between them are as follows:

  • Kagocel is not recommended to be prescribed during pregnancy and lactation. Oscillococcinum has no such contraindications;
  • Kagocel is an allopathic drug, Oscillococcinum is a homeopathic one;
  • Oscillococcinum is not prescribed to persons with sucrose and lactose intolerance;
  • Kagocel begins its active action 2 days after ingestion. The speed of the effect from the use of Oscillococcinum depends on how quickly the treatment was started after the first signs of the disease appeared;
  • exceeding the therapeutic dosage of Kagoceal leads to symptoms of an overdose. In Oscillococcinum, such phenomena have not yet been recorded.

Which is better: Kagocel or Antigrippin?

Antigrippin is a combination drug. The active components of the drug are paracetamol, chlorphenamine and ascorbic acid. The medicine has antipyretic, analgesic and anti-allergic effects. Available in powder form for solution preparation. The main indications for the appointment of Antigrippin include infectious and inflammatory diseases, accompanied by headache, fever, joint and muscle pain, runny nose and excessive sweating. The drug is not allowed to be used during pregnancy and lactation, as well as under the age of 15 years.

Kagocel and Antigrippin have the same indications for the appointment. The drugs belong to a different group of drugs, have a different composition, mechanism of action and release form. Kagocel is used as etiotropic therapy, and Antigrippin is used as symptomatic therapy. Comprehensive treatment of acute respiratory viral infections and influenza does not exclude the joint appointment of these drugs. It is recommended that you consult your doctor before using drugs.

Which is better: Kagocel or Anvimax?

Another representative of the group of combined drugs for the treatment of acute respiratory viral infections and influenza is Anvimax. The composition of the medicinal product includes:

  • paracetamol;
  • calcium gluconate monohydrate;
  • loratadine;
  • vitamin C;
  • rimantadine hydrochloride;
  • rutoside trihydrate.

Thanks to its components, Anvimax has antiviral, antipyretic, analgesic, antihistamine and angioprotective effect. Available in capsule and powder form for solution preparation. The main indications for the appointment of Anvimax are the symptoms of ARVI and influenza.

Kagocel and Anvimax have similar indications for use. The drugs belong to a different pharmacological group, have a different composition, mechanisms of action and release forms. In some cases, the joint use of Anvimax and Kagocel is allowed for the complex treatment of acute respiratory viral diseases and influenza.

Kagocel for children

In pediatric practice, Kagocel is allowed for use by patients from 3 years of age. The drug is prescribed for the treatment and prevention of ARVI and influenza symptoms. Dosage, frequency of administration and duration of the course depend on many factors. These include the child's age, illness and severity of the condition. Therefore, before buying a medicine, you should consult your doctor.

Kagocel and alcohol

Currently, there are no data indicating the absolute incompatibility of alcoholic beverages with the intake of Kagocel. However, in some cases, the use of the drug is accompanied by the appearance of weakness, increased fatigue, drowsiness and a decrease in concentration. These reactions are associated with the production of endogenous interferons. The listed symptoms are often mistaken for manifestations of a viral disease, so they are not given special importance. Drinking alcohol will increase asthenic disorders. In this regard, it is not recommended to drink alcohol during the period of taking Kagocel.

During pregnancy and lactation

There are currently no reliable data confirming the negative effect of Kagocel on the organisms of the mother and fetus. However, doctors agree that if it is possible to use another drug, then it is better not to prescribe Kagocel.

During pregnancy and lactation, it is necessary to exclude the possibility of self-medication. If signs of SARS and flu appear, you need to see a doctor. The specialist will carry out the necessary diagnostics and select the correct therapy.

Terms of sale

Kagocel belongs to non-prescription drugs. However, before purchasing it from a pharmacy, you should consult a doctor. The specialist will select the dosage, frequency of administration and determine the duration of the course of treatment.

Storage conditions

The drug should be stored in a dry place, protected from light and children, at a temperature not higher than +25 degrees Celsius.

Shelf life

The shelf life of Kagocel is 2 years from the date of manufacture of the drug. It is not recommended to use the medicinal product after the expiration date.

Manufacturer

NEARMEDIC PLUS LLC, Russia, Moscow.

List of references:

  1. State Register of Medicines;
  2. Anatomical Therapeutic Chemical Classification (ATX);
  3. Nosological classification (ICD-10);
  4. Official instructions from the manufacturer.

Few facts

ARVI (acute respiratory viral diseases) affects the upper respiratory tract. Manifested by painful sensations in the throat, dizziness, weakness and profuse lacrimation. People call this condition a cold. It has similar symptoms to the flu, but develops more slowly. The lack of timely treatment causes a severe cough, an increase in body temperature. Subsequently, complications such as sinusitis or otitis media may occur. There are many alternative methods of treatment for combating colds, but dangerous consequences can only be prevented with the help of medicines. The list of the most effective drugs also includes Kagocel, whose action is aimed at inducing the production of a special group of proteins (interferon). The active ingredient affects all cells that have antiviral properties. It can be used for preventive purposes. The kit includes packaging and instructions for use.

Pharmacodynamics

Kagocel promotes the production of gamma interferon. Affects the protective function of several types of cells (macrophages, lymphocytes (groups T and B), fibroblasts, granulocytes, and endothelium). The maximum concentration of the substance is reached after 48 hours. The circulation of a special group of proteins is maintained for five days. The concentration of the substance in the intestine differs from the production of signaling molecules in the blood serum. In the digestive organ, the production of interferon was recorded as early as 3.5 hours after the use of the medication.To achieve quick results, you need to take the medication no later than the third day after the onset of symptoms of the disease. Medication is also prescribed to prevent infection, including after contact with a likely source of infection.

Pharmacokinetics

Максимальная концентрация медикамента, спустя 24 часа после введения в организм, выявлена в печени. Лекарство также локализуется в вилочковой железе, легких, почках и селезенке, но в меньшей степени. Низкое сосредоточение зафиксировано в сердце, семенниках, головном мозге, а также плазме крови. Полупроницаемый барьер между кровью и нервной тканью затрудняет проникновение препарата в главный орган центральной нервной системы.При регулярном применении медикамента в больших дозах, объем его распределения возрастает и определяется во всех органах. Максимальная концентрация выявлена в лимфоузлах и селезенке.Кагоцел выводится из организма в среднем через 7 суток. Покидает организм преимущественно с помощью кишечника (около 90% от принятой дозы) и почками (10%). Клинические испытания не подтвердили наличие следов препарата в выдыхаемом воздухе.

Состав и форма выпуска

Кагоцел выпускают в таблетированной форме. Производитель использует ячейковую упаковку из поливинилхлорида и алюминиевой фольги, разделенную на 10 секций. Каждая таблетка содержит 12 мг активного действующего вещества. В состав также входят и дополнительные ингредиенты, такие как картофельный крахмал, кросповидон, стеарат кальция, повидон. Двояковыпуклые таблетки могут иметь различный окрас – от белого до коричневого оттенка.

Показания к применению

Препарат назначают детям старше трех лет и взрослым пациентам для лечения ОРВИ и грипп. Подходит также для устранения вирусной этиологии герпетической инфекции, но только у взрослых. Может использоваться в комбинации с другими препаратами для устранения урогенитального хламидиоза. Кагоцел также показан к применению для профилактики во время эпидемии гриппа и ОРВИ.

Побочные эффекты

Клинические случаи острой отрицательной реакции организма на прием препарата не зафиксированы. Но Кагоцел способен вызвать аллергические реакции у людей с индивидуальной непереносимостью к одному из составляющих препарата. До начала приема медикамента нужно получить консультацию у специалиста.

Contraindications

Препарат легко переносится пациентами, но все же есть группа риска. Средство не назначают во время беременности и грудного вскармливания. Запрещено использовать противовирусный медикамент детям до достижения трехлетнего возраста, а также пациентам с непереносимостью лактозы или дефицитом лактазы. Может нанести серьезный вред при глюкозо-галактозной мальабсорбации.

Storage conditions

Упаковку нужно хранить в прохладном помещении, защищенном от прямых солнечных лучей. Температура воздуха не должна превышать +25 градусов. При соблюдении всех условий лекарство можно использовать в течение четырех лет с момента выпуска. Срок годности нанесен на упаковку.

Применение в период беременности и лактации

Медикамент не рекомендуют принимать женщинам во время вынашивания ребенка и кормления грудью из-за отсутствия клинических испытаний.

Особенности терапии

Кагоцел разработан для внутреннего применения. Эффективность препарата не связана с приемом пищи. Взрослым пациентам при первых симптомах вирусной инфекции или гриппа нужно выпить две таблетки. Прием препарата следует повторить три раза в течение дня. Затем количество медикамента нужно снизить. Достаточно принимать лекарство три раза в день. Дозировка – 1 таблетка. Взрослым пациентам понадобится пройти курс длительностью 4 дня. Максимально допустимая норма - 18 таблеток за весь терапевтический период.В качестве профилактики заражения ОРВИ или гриппом препарат назначают циклами. В течение первых двух дней нужно использовать две таблетки за один прием. После чего должен последовать перерыв. Через пять дней следует повторить цикл. Продолжительность приема зависит от индивидуальных показателей. Решение должен принимать врач. Может составить всего семь дней или продлиться несколько месяцев. Кагоцел также назначают при герпесе. Взрослым нужно принимать лекарство три раза в день. Оптимальное количество – 14 мг вещества или 2 таблетки за один прием. Терапия должна составить 5 дней. Максимальная дозировка на весь период – 360 мг.Младшая возрастная категория (дети в возрасте от трех до шести лет) также могут принимать лекарство. Схема приема включает несколько этапов. Первые двое суток детям выписывают препарат два раза в день, но только по одной таблетке. После чего дозировку снижают. Можно принять медикамент только один в раз в день в дозировке 12 мг. Суммарное количество индуктора интерферона за весь период терапии не должно превышать 6 таблеток. Детям старше шести лет для лечения вирусных заболеваний выписывают медикамент на четыре дня. Общая дозировка за курс не должна превышать 120 мг или десять таблеток. В течение первых 48 часов пациент должен принять по одной таблетке три раза в день. В последующие дни дозировку снижают до одной таблетки два раза в течение дня.Предотвратить заражение детей старше трех лет можно с помощью курсов профилактики. Количество циклов назначает врач. Стандартно выписывают одну таблетку в день. Достаточно принимать препарат два дня. После чего нужно сделать перерыв, но не менее пяти дней. Профилактика может занять неделю или несколько месяцев.

Alcohol compatibility

It is undesirable to take the medication at the same time as alcoholic beverages. This combination can cause abnormalities in the functioning of the central nervous system. Ethanol has a great influence on endogenous interferons. A dangerous combination of Kagocel and alcohol can lead to neurosis, depression, retinopathy and neuropathy. The drug continues to act on the body for an average of another week after administration. Only after 7 days can beverages containing alcohol be consumed. It is important to remember that viral and infectious diseases have a strong effect on the body and can weaken the functioning of the kidneys, heart or liver.

Interaction with other medicinal products

The medication is prescribed in combination with immune system regulators, antibacterial and antiviral drugs.

Overdose

Cases of drug overdose have not been recorded, but a significant excess of the norm can cause vomiting, seizures in the umbilical zone, dizziness. To eliminate the listed symptoms, you need to rinse the stomach and provide an abundant drink.

Analogs

The following drugs have a similar effect in the treatment of viral diseases - Acigerpin, Atsik-ophtal, Acyclostad, Acyclovir, Adapromin, Afludol, Adapromin, Afludol.

Terms of sale

The drug is sold in pharmacies without a prescription from the attending physician.

Testimonials

Patients note the effectiveness of taking Kagocel, but only in combination with other medicines. Otherwise, the viral disease proceeds with standard symptoms. Prophylactic administration also practically does not prevent infection. After using the drug, several users reported short-term side effects in the form of headaches and weakness. Doctors are proving the effectiveness of the drug in the treatment of herpes. Clinical studies have shown that taking the medication in combination with other drugs reduces the treatment period in half. At the end of the trial, there was also a low relapse rate in users taking Kagocel.

Prices for Kagocel and delivery methods in Moscow and other cities of Russia

Pick up your order at the nearest pick-up point or

pharmacy WER

(Moscow city)

Price: from 212 rub.

Kagocel: how to take and contraindications

Antiviral drug with immunomodulatory properties. Eliminates acute symptoms of respiratory infections, promotes the production of protective antibodies in the body. Rarely causes side reactions, it is used to treat children from 3 years of age.

Content:

Kagocel: composition and dosage form of the drug

The active ingredient of the drug is sodium salt based on carmoxymethylcellulose and a polyphenol compound of plant origin. Kagocel stimulates the formation of human interferons, immune proteins that suppress harmful microflora:

  • macrophages;

  • lymphocytes;

  • endothelial cells;

  • granulocytes;

  • fibroblasts.

The drug has antimicrobial, immunomodulatory, radioprotective effect. It is active against the causative agents of ARVI and herpes simplex.

Kagocel is available in the form of tablets for oral administration: biconvex, light brown in color with small inclusions. Packing - contour blisters with 10 cells.

The drug tablet contains 12 mg of gossypol copolymer and auxiliary components:

  • starch;

  • calcium salts;

  • lactose;

  • povidone.

Mechanism of action

After administration, the active substance is concentrated during the day mainly in the tissues of the liver, lungs, spleen, and kidneys. A small amount accumulates in muscles, brain and blood plasma.

The protective level of interferons grows in the body for 48 hours and lasts up to 5 days from the moment of taking the medicine. This property necessitates the appointment of Kagocel at an early stage of the disease - no later than 4 days from the moment of infection.

It is excreted from the body through the intestines. It is not deposited in tissues, has no toxic effect, does not cause cell mutations.

What diseases is Kagocel used for?

An antiviral agent is prescribed to treat:

  • flu;

  • acute respiratory infections;

  • in adults: herpes infections;

  • in complex therapy: intestinal inflammation of viral origin.

Kagocel is also indicated for the prevention of the development of ARVI during the period of seasonal epidemics, in contact with probable infected.

How to take Kagocel

The tablets are taken orally without chewing or crushing into parts. Wash down with plenty of water. Meal time does not matter. Gastric juice does not affect the absorption of the drug into the bloodstream.

For prophylaxis, adults and adolescents over 12 years old are recommended to use Kagocel in cycles:

This scheme contributes to the formation and maintenance of the body's defenses for a week after the next use of the medicine.

For the treatment of acute respiratory viral infections are prescribed:

A total of 18 tablets are enough for a 4-day course. Longer treatment is irrational.

When treating herpes, Kagocel is drunk for 5 days: 2 pills three times a day. The course is designed for 30 tablets.

How to take Kagocel for children

Children 3-6 years old with flu are prescribed:

Children 6-12 years old can take:

For the prevention of diseases in childhood, 2 tablets are enough for 7 days: 1 pc. daily for the first 2 days, then a 5-day interval. Preventive treatment can be repeated throughout the epidemic season.

Is Kagocel allowed during pregnancy

Despite its low toxicity, the drug is not recommended for use by pregnant women, since its effect on the fetus has not been sufficiently studied. For the same reason, you should not use Kagocel during breastfeeding.

Contraindications

In addition to periods of pregnancy and breastfeeding, contraindications include:

  • age up to 3 years;

  • individual intolerance to the components of the drug;

  • persistent enzymatic disorders: lactase deficiency, malabsorption syndrome.

Is it possible to combine Kagocel with alcohol

There are no data on the interaction of the components of the drug with ethanol and the formation of toxic compounds when used together. However, under the influence of alcohol, the mechanism of interferon formation can be disrupted. In such cases, the therapeutic effect of Kagocel will be insufficient or come to naught.

In addition, alcohol can increase the risk of allergies and side effects while taking the medication. For these reasons, one should refuse alcohol for a period of at least 5 days from the moment of the last intake of Kagocel.

Ingavirin or Kagocel

Ingavirin is active in the prevention and treatment of influenza serotypes A and B, as well as some other isolated respiratory viral diseases. However, it is ineffective for non-specific therapy, while Kagocel helps prevent most types of ARVI.

Does Arbidol help better than Kagocel

Both drugs are similar in their mechanism of action and effectiveness. But Arbidol has a longer list of contraindications and is included in list B, which requires special care.

Amiksin or Kagocel: what to choose

Amiksin is characterized by a faster formation of a protective titer of interferons after administration - within 24 hours. Its use is more justified for urgent prophylaxis. But this medicine cannot be used in pediatrics for babies under 7 years old. Kagocel is suitable for children over 3 years old.

Kagocel or Ergoferon: which will help faster

The spectrum of the therapeutic action of Ergoferon is much wider. In addition, it is endowed with anti-inflammatory and antihistamine properties, and it is allowed for use from 6 months. Objectively, this drug is more effective than Kagocel, but higher in cost.

How much is Kagocel

Prices for a package of a drug of 10 tablets in Russia vary from 180 to 250 rubles. In the Ukrainian regions, a medicine is more expensive: within UAH 150-180.

A pharmacist at one of the Kaliningrad pharmacies demonstrates a package with the drug "Kagocel". Photo: Igor Zarembo / RIA Novosti

The drug Kagocel has taken a firm place on the shelves of Russian pharmacies. It has been prescribed for many years to children and adults with acute respiratory viral infections and influenza, as well as herpes. It is worth asking at the pharmacy "what to take for immunity?" According to experts, it is one of the twenty best-selling drugs in Russia.

At the same time, the controversy around Kagocel does not subside in medical circles: the advocates of evidence-based medicine insist that there is no scientific evidence of the drug's effectiveness, while public figures directly related to the Nearmedic manufacturing company claim the opposite: the necessary studies have been carried out, efficiency has been proven, and all claims against Kagocel have been paid for by competitors.

This year, another (though not new) accusation against the drug has become widespread on the network. Kagocel allegedly causes infertility.

How effectiveness is tested

Photo: PA Images / TASS

In the modern world, the presence of studies in the course of which a drug somehow demonstrated a therapeutic or prophylactic effect is not yet a reason to declare it effective.

Typically, a candidate for becoming a medicine goes through several stages.

Its action is studied in vitro: scientists observe how a potential therapeutic agent interacts with living cells of the body and with pathogens. Convinced that it has therapeutic potential, it is tested in laboratory animals.

If a drug candidate does not cause serious adverse reactions in animals, it is tested in humans.

Typically, scientists first observe the effect of a drug on small groups of people, and then carefully plan and conduct clinical trials according to very strict guidelines. Let's talk about the most important ones.

First, such research is carried out in three stages.

Phase I and II clinical trials may involve a small sample of participants. As for the phase III tests, they should be:

a) multicenter (which means research centers in different countries);

b) carried out on a large number of participants (thousands) in order to minimize possible statistical errors in determining the effectiveness of the drug, as well as to establish all possible, including relatively rare, for example, 1: 1000, undesirable side effects.

Such requirements are imposed on clinical trials by certifying agencies in all developed countries. They take the standards of the FDA, the US Food and Drug Administration as a model.

Secondly, clinical trials must have a control group.

This means that comparable numbers of participants are taking the candidate drug and the placebo (dummy). This separates the real effect of the drug from the occasional improvement.

In this case, the groups should be randomized, that is, approximately coincide in various parameters. It is impossible for one group to be dominated by men, in another by women, in one by participants aged 20 to 30, in another by 40 to 50, in one by rich people, in the other by people with low incomes.

Finally, clinical trials should be double-blind studies. This means that neither the patients themselves, nor the doctors who assess the condition of the participant at different stages of his admission, do not need to know what they are dealing with, with a real agent or with a placebo.

This is absolutely necessary to ensure that the results are not influenced by the "human factor".

Only after passing all three phases of double-blind randomized controlled trials can a drug qualify for approval by the FDA or the relevant European agencies.

No pharmaceutical company can claim to be effective unless it meets the very strict current standard outlined above.

What is your evidence?

The child is sick with the flu. Photo: Vladimir Smirnov / TASS

Kagocel's research is mostly in vitro research, animal model research and observational research. Only a few of these are clinical trials, and none of the age cohorts has conducted large-sample three-phase trials.

In the study "Clinical efficacy of Kagocel in ARVI with stenosing laryngotracheitis in children," the sample consisted of only 60 children aged 6 to 13 years (29 in the Kagocel group), which is acceptable for stage I clinical trials.

Domestic flu vaccines: advice for those who decided to get vaccinated

If the result is positive, it should be followed by more numerous samples of II and III phases. However, since no further trials were conducted, the conclusion about the effectiveness seems premature, especially since, in accordance with the results obtained, the difference in the duration of the symptoms of SARS and laryngotracheitis between the Kagocel group and the placebo group was no more than a day.

Considering that the drug was taken by only 29 children, then the final conclusion about the safety of the drug after testing on such a small sample cannot be made, since it is impossible to trace even those side effects that occur with a frequency of 1: 100, not to mention the more rare ...

The situation is similar with the study "Clinical efficacy of the drug" Kagocel "against influenza and ARVI in children from 2 to 6 years old. The drug was also studied in a cohort of only 60 children. There are also no downstream trials for this age group.

There is another study of the same authors in 2012 on the same modest sample and their work for the age group from 6 years on a sample of 120 participants (2009) to assess the preventive effectiveness of Kagocel, which is also not valid samples for final conclusions about the effectiveness and safety in accordance with international standards.

On adult cohorts, two clinical trials were conducted "Therapeutic efficacy of" Kagocel "in the treatment of patients with uncomplicated influenza and influenza complicated by angina" and "Use of the drug" Kagocel "for the treatment and prevention of influenza and other acute respiratory viral infections" (not available in the public domain) ...

The first - on a sample of 264 people, the second - on a sample of 331 people. This is the only Kagocel's study carried out on a sample that meets the standards, however, it is also a one-stage study, and in addition, it evaluates the effectiveness not in treatment, but in prevention.

Production of the antiviral agent "Kagocel". Photo: Valery Melnikov / RIA Novosti

Thus, even if there were no more claims to the design of studies, their extremely small number (especially for children) already makes them do not meet international standards for this kind of scientific work.

There is, however, another very serious limitation. Research is simple blind, not double blind, which does not guarantee objectivity and does not meet international standards in any way.

And finally, as noted above, according to research results, the difference in the duration of symptoms at best was on the order of one day - this is a rather modest result for a particular patient, taking into account that he pays for this not cheap drug, as a rule, from your pocket.

There is one more very important circumstance. Influenza and ARVI are self-limiting infections, that is, they have a limited duration and in the vast majority of cases pass without intervention (excluding complications).

In this situation, the requirements for evidence of effectiveness are particularly stringent. We must be sure that the disease did not go away by itself, but as a result of the investigational therapy, and in the case of Kagocel we do not observe compliance even with the basic rules.

So, the effectiveness of Kagocel, alas, is not proven.

It is possible that someday Nearmedic will conduct clinical trials according to all the rules and prove to us the usefulness of its product, but so far, sales success is based on skillful marketing, and not on solid scientific evidence.

What about security?

Does Kagocel threaten infertility?

Customers in the Moscow pharmacy hypermarket of the 36.6 chain. Photo: Artem Geodakyan / TASS

The active ingredient of the drug is gossypol (a natural compound found in cotton), associated with oxidized carboxymethyl cellulose.

Gossypol is capable of inhibiting spermatogenesis and has even been studied in clinical studies for its use as a male contraceptive. However, this idea had to be abandoned. Firstly, in 20% of cases, the effect of the drug was irreversible, that is, it made the man infertile forever, and secondly, according to preliminary data, there is a possibility that gossypol has genetic toxicity.

The manufacturer of Kagocel claims that gossypol is included in the composition of the drug in a bound form and is not released in the process of chemical transformations in the body, and therefore cannot inhibit spermatogenesis. At the same time, a number of experts, for example, the authors of the work "Leaders in the sale of OTC drugs and their safety issues", question this statement.

If we assume that the high molecular weight Kagocel in the process of absorption in the gastrointestinal tract is broken down into smaller molecules, then, according to the doctor of medical sciences, professor at RUDN University E. Ushkalova and her co-author, a researcher at the N.N. VI Kulakova N. Chukhareva, taking the drug "in the prepubertal and pubertal period (that is, in children and adolescents) is even more dangerous from the point of view of the effect on reproductive functions than at puberty."

The authors of the article believe that until the results of targeted studies to study the long-term effects of Kagocel's use in males, including children and adolescents, are obtained, the drug cannot be characterized as safe with a high degree of certainty.

Bifurcation of the Ministry of Health

At the Pharmacy in Novosibirsk. Photo: Kirill Kukhmar / TASS

Kagocel is approved by the Ministry of Health of Russia as an antiviral immunomodulatory drug and is recommended for the treatment and prevention of ARVI (acute respiratory viral infections) and influenza in adults and children from 3 years of age, as well as for the treatment of herpes. "

Moreover, in 2015, the drug was included by the same Ministry of Health on the list of essential drugs for medical use - VED!

In 2018, however, the Union of Pediatricians under the auspices of the same Ministry of Health issued guidelines entitled "Acute respiratory viral infection (ARVI) in children."

This is what the authors of this document write: “ARVI is the most common reason for the use of various drugs and procedures, most often unnecessary, with unproven action, often causing side effects. Therefore, it is very important to educate parents on the benign nature of the disease and to inform the expected duration of the symptoms present, as well as to convince them of the sufficiency of minimal intervention. "

Further, the authors pay attention to various groups of drugs, including immunomodulators, to which Kagocel belongs.

“Antiviral drugs with immunotropic action do not have a significant clinical effect, their appointment is impractical. ... The results of studies on the effectiveness of the use of immunomodulators in respiratory infections, as a rule, show an unreliable effect. "

In other words, the Ministry of Health recommends, but the Ministry of Health does not recommend, the use of Kagocel for ARVI.

That, perhaps, is all that in general terms can be said today about this drug. It remains to wish its creators, finally, to conduct valid trials and to familiarize the scientific and medical community and potential consumers with their results, and our readers - to make informed decisions about the treatment of ARVI and influenza.

To do this, it will be useful to familiarize yourself with the aforementioned document, based on modern scientific data, in which the Ministry of Health of the 2018 version disputes the opinion of the Ministry of Health of the 2015 version.

Добавить комментарий